Peritoneal equilibration test with conventional ‘low pH/high glucose degradation product’ or with biocompatible ‘normal pH/low glucose degradation product’ dialysates: does it matter?
VAN OVERMEIRE, Lionel; Goffin, Eric; Krzesinski, Jean-Marieet al.
2013 • In Nephrology Dialysis Transplantation, p. 1946-51
albumin; beta-2 microglobulin; biocompatible solutions; peritoneal dialysis; peritoneal equilibration test
Abstract :
[en] Abstract
Background. The evaluation of the peritoneal transport characteristics is mandatory in peritoneal dialysis (PD) patients. This is usually performed in routine clinical practice with a peritoneal equilibration test (PET) using conventional dialysates, with low pH and high glucose degradation product (GDP) concentrations. An increasing proportion of patients are now treated with biocompatible dialysates, i.e. with physiological pH and lower GDP concentrations. This questions the appropriateness to perform a PET with conventional solutions in those patients. The aim of our study is to compare the results of the PET using biocompatible and conventional dialysates, respectively.
Methods. Nineteen stable PD patients (13 males, 6 females; mean age: 67.95 ± 2.36 years, mean body surface area: 1.83 ± 0.04 m2, dialysis vintage: 2.95 ± 0.19 years) were included, among which 10 were usually treated with biocompatible and 9 with conventional solutions. Two PETs were performed, within a 2-week interval, in each patient. PET sequence (conventional solution first or biocompatible solution first) was randomized in order to avoid ‘time bias’. Small (urea, creatinine and glucose), middle (beta-2-microglobulin) and large molecules’ (albumin and alpha-2-macroglobulin) dialysate/plasma (D/P) concentration ratios and clearances were measured during each PET. Ultrafiltration (UF) and sodium filtration were also recorded. Results of both tests were compared by the Wilcoxon paired test.
Results. No statistical difference was found between both dialysates for small molecule transport rates or for sodium filtration and UF. However, a few patients were not similarly classified for small-solute transport characteristics within the PET categories. Beta-2-microglobulin and albumin D/P ratios at different time points of the PET were significantly higher with the biocompatible, when compared with the conventional, solutions: 0.10 ± 0.03 versus 0.08 ± 0.02 (P < 0.01) and 0.008 ± 0.003 versus 0.007 ± 0.003 (P = 0.01), respectively. A similar difference was also observed for beta-2-microglobulin that was higher with biocompatible dialysates (1.04 ± 0.32 versus 0.93 ± 0.32 mL/min, respectively).
Conclusion. Peritoneal transport of water and small solutes is independent of the type of dialysate which is used. This is not the case for the transport of beta-2-microglobulin and albumin that is higher under biocompatible dialysates. Vascular tonus modification could potentially explain such differences. The PET should therefore always be carried out with the same dialysate to make longitudinal comparisons possible.
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Saint-Remy, Annie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Bovy, Philippe; Centre Hospitalier Chrétien > Néphrologie
Cornet, Georges; Centre Hospitalier Peltzer-La Tourelle > Néphrologie
BOVY, Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Language :
English
Title :
Peritoneal equilibration test with conventional ‘low pH/high glucose degradation product’ or with biocompatible ‘normal pH/low glucose degradation product’ dialysates: does it matter?
Brimble KS, Walker M, Margetts PJ et al. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17: 2591-2598
Chung SH, Chu WS, Lee HA et al. Peritoneal transport characteristics, comorbid diseases and survival in CAPD patients. Perit Dial Int 2000; 20: 541-547
Perez-Fontan M, Rodriguez-Carmona A, Barreda D et al. Peritoneal protein transport during the baseline peritoneal equilibration test is an accurate predictor of the outcome of peritoneal dialysis patients. Nephron Clin Pract 2010; 116: c104-c113
Goffin E, Combet S, Jamar F et al. Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport. Am J Kidney Dis 1999; 33: 383-388
Parikova A, Smit W, Struijk DG et al. The contribution of free water transport and small pore transport to the total fluid removal in peritoneal dialysis. Kidney Int 2005; 68: 1849-1856
Parikova A, Smit W, Struijk DG et al. Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure. Kidney Int 2006; 70: 1988-1994
Smit W, Langedijk MJ, Schouten N et al. A comparison between 1.36% and 3.86% glucose dialysis solution for the assessment of peritoneal membrane function. Perit Dial Int 2000; 20: 734-741
Smit W, van Dijk P, Langedijk MJ et al. Peritoneal function and assessment of reference values using a 3.86% glucose solution. Perit Dial Int 2003; 23: 440-449
Smit W, Struijk DG, Ho-Dac-Pannekeet MM et al. Quantification of free water transport in peritoneal dialysis. Kidney Int 2004; 66: 849-854
Smit W, Schouten N, van den Berg N et al. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study. Perit Dial Int 2004; 24: 562-570
Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
Jones S, Holmes CJ, Krediet RT et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-1538
Rippe B, Simonsen O, Heimburger O et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357
Fan SL, Pile T, Punzalan S et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73: 200-206
Krediet RT. Biocompatibility and peritoneal transport. Perit Dial Int 2009; 29: 147-149
La Milia V, Limardo M, Crepaldi M et al. Effects of ionized sodium concentrations on ultrafiltration rate in peritoneal dialysis using lactate and lactate/bicarbonate solutions. Perit Dial Int 2009; 29: 158-162
Parikova A, Struijk DG, Zweers MM et al. Does the biocompatibility of the peritoneal dialysis solution matter in assessment of peritoneal function? Perit Dial Int 2007; 27: 691-696
Mujais S, Nolph K, Gokal R et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20 (Suppl 4): S5-S21
Westra WM, Smit W, Zweers MM et al. Diffusion correction of sodium sieving applicable in a peritoneal equilibration test. Adv Perit Dial 2003; 19: 6-9
Waniewski J, Werynski A, Heimburger O et al. Simple models for description of small-solute transport in peritoneal dialysis. Blood Purif 1991; 9: 129-141
Waniewski J, Werynski A, Heimburger O et al. A comparative analysis of mass transport models in peritoneal dialysis. ASAIO Trans 1991; 37: 65-75
Covic A, Bammens B, Lobbedez T et al. Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant 2010; 25: 1757-1759
Krediet RT, Imholz AL, Struijk DG et al. Effects of tracer, volume, osmolarity and infection on fluid kinetics during CAPD. Blood Purif 1992; 10: 173-181
Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-438
Xu B, Chibber R, Ruggiero D et al. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 1289-1291
Zakaria eR, Patel AA, Li N et al. Vasoactive components of dialysis solution. Perit Dial Int 2008; 28: 283-295
Rosengren BI, Rippe A, Rippe C et al. Transvascular protein transport in mice lacking endothelial caveolae. Am J Physiol Heart Circ Physiol 2006; 291: H1371-H1377
Mortier S, De Vriese AS, Van de, Voorde J et al. Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002; 13: 480-489